Search results
Results from the WOW.Com Content Network
Minitran 4-25: 4 mg Perphenazine and 25 mg Amitriptyline hydrochloride in each tablet. Minitran is also a pharmaceutical drug for the treatment of Angina, manufactured by 3M. It contains glyceryl trinitrate and is sold in patch form. It is sold in the following strengths: Minitran 5 contains 18 mg of glyceryl trinitrate and delivers 5 mg in 24 ...
This D 2 blockade results in antipsychotic, antiemetic and other effects. Hyperprolactinemia is a side effect of dopamine antagonists as blockade of D 2 receptors within the tuberoinfundibular pathway results in increased plasma levels of prolactin due to increased secretion by lactotrophs in the anterior pituitary.
Usual oral forms are tablets (2, 4, 8, 16 mg) and liquid concentrate (4 mg/ml). The 'Perphenazine injectable USP' solution is intended for deep intramuscular (i.m.) injection, for patients who are not willing to take oral medication or if the patient is unable to swallow.
Carbinoxamine is an antihistamine and anticholinergic agent.It is used for hay fever, vasomotor rhinitis, mild urticaria, angioedema, dermatographism and allergic conjunctivitis.
Benidipine is initially licensed for use in Japan and selected Southeast Asian countries and later in Turkey, where it is sold as 4 mg tablets. References [ edit ]
Adult: Per tablet contains flupentixol 0.5 mg and melitracen 10 mg: 1 tablet in the morning and at midday. May double morning dose in severe cases. Not to exceed 4 tablets daily. [citation needed] Elderly: Per tablet contains flupentixol 0.5 mg and melitracen 10 mg: 1 tablet in the morning. For severe cases: 1 tablet in the morning and at midday.
Cyproheptadine has been reported to block 85% of 5-HT 2 receptors in the human brain at a dose of 4 mg three times per day (12 mg/day total) and to block 95% of 5-HT 2 receptors in the human brain at a dose of 6 mg three times per day (18 mg/day total) as measured with positron emission tomography (PET). [32]
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required, by section 202 of that Act, for substances to be placed in this schedule: